| Species |
Human |
| Protein Construction |
IGF-BP-3 (Gly28-Lys291)
Accession # P17936 |
|
| Purity |
> 98% as analyzed by SDS-PAGE
> 98% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200.0 ng/ml, corresponding to a specific activity of > 5.0 × 103 IU/mg in the presence of 15.0 ng/ml of rHuIGF-II. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
28.8 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. |
| Synonyms |
IGFBP3; BP-53; IBP3; insulin like growth factor binding protein 3 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
